Charles Schwab’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-30,113
Closed -$1.59M 3425
2020
Q3
$1.59M Sell
30,113
-591
-2% -$36.5K ﹤0.01% 2571
2020
Q2
$1.88M Buy
30,704
+1,586
+5% +$91.7K ﹤0.01% 2449
2020
Q1
$1.65M Sell
29,118
-25,016
-46% -$1.43M ﹤0.01% 2337
2019
Q4
$3.08M Buy
54,134
+5,541
+11% +$294K ﹤0.01% 2263
2019
Q3
$2.6M Buy
48,593
+6,476
+15% +$377K ﹤0.01% 2296
2019
Q2
$2.52M Buy
42,117
+1,389
+3% +$87.4K ﹤0.01% 2291
2019
Q1
$2.54M Sell
40,728
-5,516
-12% -$365K ﹤0.01% 2283
2018
Q4
$2.8M Hold
46,244
﹤0.01% 2196
2018
Q3
$2.71M Sell
46,244
-182
-0.4% -$9.29K ﹤0.01% 2332
2018
Q2
$2.08M Buy
46,426
+3,514
+8% +$151K ﹤0.01% 2366
2018
Q1
$1.9M Hold
42,912
﹤0.01% 2352
2017
Q4
$1.86M Buy
42,912
+1,100
+3% +$49.4K ﹤0.01% 2336
2017
Q3
$1.95M Buy
41,812
+3,541
+9% +$170K ﹤0.01% 2299
2017
Q2
$1.9M Hold
38,271
﹤0.01% 2238
2017
Q1
$2.1M Sell
38,271
-4,739
-11% -$251K ﹤0.01% 2183
2016
Q4
$2.4M Sell
43,010
-1,700
-4% -$81.7K ﹤0.01% 2099
2016
Q3
$2.04M Hold
44,710
﹤0.01% 2120
2016
Q2
$1.79M Hold
44,710
﹤0.01% 2133
2016
Q1
$1.56M Hold
44,710
﹤0.01% 2177
2015
Q4
$1.92M Hold
44,710
﹤0.01% 2103
2015
Q3
$1.95M Buy
44,710
+2,700
+6% +$146K ﹤0.01% 2078
2015
Q2
$2.17M Sell
42,010
-7,405
-15% -$316K ﹤0.01% 2039
2015
Q1
$1.94M Hold
49,415
﹤0.01% 2072
2014
Q4
$1.91M Hold
49,415
﹤0.01% 2037
2014
Q3
$1.75M Buy
49,415
+7,875
+19% +$231K ﹤0.01% 2042
2014
Q2
$1.12M Buy
+41,540
New +$1.08M ﹤0.01% 2263

Other funds holding BSTC

Charles Schwab's BSTC Position: Q4 2020 in Review

Charles Schwab sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2020, closing a stake of 30,113 shares — an estimated $1.59M sold.

Charles Schwab first reported a position in BSTC in Q2 2014 and held it in 26 quarters. The position peaked at $3.08M in Q4 2019. 1 fund tracked by Wall St. Rank holds BSTC as of Q4 2020.

  • Charles Schwab reported no remaining BioSpecifics Technologies Corp. position as of Q4 2020 after selling out during the quarter.
  • Charles Schwab sold 30,113 BioSpecifics Technologies Corp. shares in Q4 2020, an estimated $1.59M.
  • Charles Schwab first reported a position in BioSpecifics Technologies Corp. in Q2 2014 and held it in 26 quarters.
  • Charles Schwab's BioSpecifics Technologies Corp. position peaked at $3.08M in Q4 2019.
  • 1 fund tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2020.

Based on Charles Schwab's 13F filing for Q4 2020, filed 16 Feb 2021.